

Veronica Villani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1806408/publications.pdf>

Version: 2024-02-01

54
papers

1,129
citations

304743

22
h-index

434195

31
g-index

55
all docs

55
docs citations

55
times ranked

1794
citing authors

#	ARTICLE	IF	CITATIONS
1	A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 124.	8.6	66
2	Quality of Care and Rehospitalization Rate in the Last Stage of Disease in Brain Tumor Patients Assisted at Home: A Cost Effectiveness Study. <i>Journal of Palliative Medicine</i> , 2012, 15, 225-227.	1.1	54
3	Cognitive impairment in primary brain tumors outpatients: a prospective cross-sectional survey. <i>Journal of Neuro-Oncology</i> , 2013, 112, 455-460.	2.9	53
4	IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. <i>Journal of Neuro-Oncology</i> , 2014, 118, 377-383.	2.9	53
5	Epilepsy in the end-of-life phase in patients with high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2013, 111, 83-86.	2.9	51
6	Therapeutic strategies in migraine patients with mood and anxiety disorders: clinical evidence. <i>Neurological Sciences</i> , 2010, 31, 95-98.	1.9	46
7	Primary headache and multiple sclerosis: preliminary results of a prospective study. <i>Neurological Sciences</i> , 2008, 29, 146-148.	1.9	43
8	Predictors of survival and effect of short (40ÂGy) or standard-course (60ÂGy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). <i>Journal of Neuro-Oncology</i> , 2015, 125, 359-367.	2.9	42
9	Home palliative care and end of life issues in glioblastoma multiforme: results and comments from a homogeneous cohort of patients. <i>Neurosurgical Focus</i> , 2014, 37, E5.	2.3	41
10	Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group. <i>Epilepsy and Behavior</i> , 2017, 73, 83-89.	1.7	39
11	Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas. <i>Neuroradiology</i> , 2015, 57, 1269-1280.	2.2	37
12	Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial. <i>Head and Neck</i> , 2016, 38, E2118-21.	2.0	32
13	Perampanel in patients with brain tumor-related epilepsy in real-life clinical practice: a retrospective analysis. <i>International Journal of Neuroscience</i> , 2019, 129, 593-597.	1.6	32
14	Perampanel Confirms to Be Effective and Well-Tolerated as an Add-On Treatment in Patients With Brain Tumor-Related Epilepsy (PERADET Study). <i>Frontiers in Neurology</i> , 2020, 11, 592.	2.4	32
15	Primary headache in Emergency Department: prevalence, clinical features and therapeutical approach. <i>Journal of Headache and Pain</i> , 2005, 6, 287-289.	6.0	29
16	Zonisamide for Migraine Prophylaxis in Topiramate-Intolerant Patients: An Observational Study. <i>Headache</i> , 2011, 51, 287-291.	3.9	28
17	The Impact of Interferon Beta and Natalizumab on Comorbid Migraine in Multiple Sclerosis. <i>Headache</i> , 2012, 52, 1130-1135.	3.9	28
18	Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study. <i>Breast Cancer Research</i> , 2017, 19, 46.	5.0	28

#	ARTICLE	IF	CITATIONS
19	Factors affecting 18F FDOPA standardized uptake value in patients with primary brain tumors after treatment. <i>Nuclear Medicine and Biology</i> , 2015, 42, 355-359.	0.6	26
20	Therapeutic strategies in migraine patients with mood and anxiety disorders: physiopathological basis. <i>Neurological Sciences</i> , 2010, 31, 99-101.	1.9	24
21	Rehabilitation pathways in adult brain tumor patients in the first 12 months of disease. A retrospective analysis of services utilization in 719 patients. <i>Supportive Care in Cancer</i> , 2016, 24, 4801-4806.	2.2	24
22	Central mechanism of action of antimigraine prophylactic drugs. <i>Neurological Sciences</i> , 2008, 29, 123-126.	1.9	23
23	Efficacy and tolerability of pregabalin as preventive treatment for migraine: a 3-month follow-up study. <i>Journal of Headache and Pain</i> , 2011, 12, 521-525.	6.0	22
24	Great occipital nerve blockade for cluster headache in the emergency department: case report. <i>Journal of Headache and Pain</i> , 2006, 7, 98-100.	6.0	20
25	The influence of patient sex on clinical approaches to malignant glioma. <i>Cancer Letters</i> , 2020, 468, 41-47.	7.2	20
26	Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 455-462.	2.9	17
27	A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 527-535.	2.9	16
28	Determinants of the severity of comorbid migraine in multiple sclerosis. <i>Neurological Sciences</i> , 2012, 33, 1345-1353.	1.9	15
29	The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma. <i>Disease Markers</i> , 2015, 2015, 1-6.	1.3	14
30	Tapentadol in neuropathic pain cancer patients: a prospective open label study. <i>Neurological Sciences</i> , 2017, 38, 1747-1752.	1.9	14
31	The "Repeater" Phenomenon in Migraine Patients: A Clinical and Psychometric study. <i>Headache</i> , 2010, 50, 348-356.	3.9	12
32	Quality of life of multiple sclerosis patients with comorbid migraine. <i>Neurological Sciences</i> , 2011, 32, 149-151.	1.9	12
33	Headache as a presenting symptom of glioma: A cross-sectional study. <i>Cephalalgia</i> , 2018, 38, 730-735.	3.9	12
34	Comorbidities in elderly patients with glioblastoma: a field-practice study. <i>Future Oncology</i> , 2019, 15, 841-850.	2.4	12
35	Home care for brain tumor patients. <i>Neuro-Oncology Practice</i> , 2014, 1, 8-12.	1.6	11
36	The use of ID migraine questionnaire in patients with multiple sclerosis. <i>Neurological Sciences</i> , 2011, 32, 269-273.	1.9	10

#	ARTICLE	IF	CITATIONS
37	Single-blind, randomized, pilot study combining shiatsu and amitriptyline in refractory primary headaches. <i>Neurological Sciences</i> , 2017, 38, 999-1007.	1.9	9
38	Migraine in the emergency department: a psychometric study of a migraine "repeaters" sample. <i>Journal of Headache and Pain</i> , 2005, 6, 301-303.	6.0	8
39	Vastus lateralis myofascial free flap for tongue reconstruction and hypoglossal-femoral anastomosis: neurophysiological study. <i>Neurological Sciences</i> , 2019, 40, 553-559.	1.9	8
40	Open Kyphoplasty for Metastatic Spine Disease: A Retrospective Clinical Series. <i>World Neurosurgery</i> , 2019, 127, e751-e760.	1.3	7
41	Neurocognitive evaluation in older adult patients affected by glioma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 701-708.	1.0	7
42	MGMT Promoter Methylation and IDH1 Mutations Do Not Affect [18F]FDOPA Uptake in Primary Brain Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7598.	4.1	7
43	Migraine and lifestyle in childhood. <i>Neurological Sciences</i> , 2015, 36, 97-100.	1.9	6
44	Kyphoplasty with purified silicone VK100 (Elastoplasty) to treat spinal lytic lesions in cancer patients: A retrospective evaluation of 41 cases. <i>Clinical Neurology and Neurosurgery</i> , 2018, 171, 184-189.	1.4	6
45	Peripheral mechanism of action of antimigraine prophylactic drugs. <i>Neurological Sciences</i> , 2008, 29, 127-130.	1.9	5
46	Temozolomide Low-dose Chemotherapy in Newly Diagnosed Low-grade Gliomas: Activity, Safety, and Long-term Follow-up. <i>Tumori</i> , 2017, 103, 255-260.	1.1	5
47	From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study. <i>European Neurology</i> , 2014, 71, 233-241.	1.4	4
48	Palliative and Supportive Care of Patients with Intracranial Glioma. <i>Progress in Neurological Surgery</i> , 2018, 31, 229-237.	1.3	4
49	Multidomain and long-term cognitive evaluation in malignant glioma patients. <i>Future Oncology</i> , 2022, , .	2.4	4
50	Phase II study of weekly carboplatin in pretreated adult malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2019, 144, 211-216.	2.9	3
51	Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasible? Results from AINO study (Italian Association for Neuro-Oncology). <i>Journal of Neurology</i> , 2021, 268, 2866-2875.	3.6	3
52	Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1272-1275.	1.3	2
53	A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?. <i>Future Oncology</i> , 2019, 15, 1717-1727.	2.4	1
54	Neutrophil-to-lymphocyte ratio, Factor VIII and Antithrombin III: inflammatory-clotting biomarkers in glioma. <i>EXCLI Journal</i> , 2021, 20, 1152-1169.	0.7	1